

Corporate Profile (As of June 30, 2021)

Name	Sumitomo Dainippon Pharma Co., Ltd.
Establishment	May 14, 1897
Date of merger	October 1, 2005
Representative	Hiroshi Nomura, Representative Director, President and CEO
Number of employees	3,109 (7,032: consolidated)
Osaka head office	6-8, Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan TEL: +81-6-6203-5321 FAX: +81-6-6202-6028
Tokyo head office	13-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8356, Japan TEL: +81-3-5159-2500 FAX: +81-3-5159-2945
Capital	¥22.4 billion
Total number of shares issued	397,900,154
Stock exchange listing	Tokyo Stock Exchange
Securities code	4506
Fiscal year-end	March 31


Ordinary general meeting of shareholders June

Main banks Sumitomo Mitsui Banking Corporation
Sumitomo Mitsui Trust Bank, Limited
MUFG Bank, Ltd.

Key facilities Osaka Head Office (Osaka)
Tokyo Head Office (Tokyo)
13 Branches,
2 Plants (Mie, Oita),
2 Research Laboratories (Osaka),
2 Distribution Centers (Hyogo, Saitama)

Businesses (Consolidated)
1. Manufacturing and sales of pharmaceuticals
2. Related businesses
(Manufacturing and sales of food ingredients, food additives, veterinary medicines, and others)

Composition of revenue (Consolidated: Fiscal year ended March 31, 2021)



Major consolidated subsidiaries (Japan)

	Establishment	Ownership	Fiscal year-end	Number of employees	Businesses
DSP GOKYO FOOD & CHEMICAL Co., Ltd.	Oct 1947	100%	March 31	208	Manufacturing and sales of food ingredients, food additives, chemical product materials, etc.
DS Pharma Animal Health Co., Ltd.	Jul 2010	100%	March 31	98	Manufacturing, and sales of veterinary medicines, etc.
DS Pharma Promo Co., Ltd.	Jun 1998	100%	March 31	42	Manufacturing and sales of pharmaceuticals, etc.

Major consolidated subsidiaries (Overseas)

	Establishment	Ownership	Fiscal year-end	Number of employees	Businesses
Sumitomo Dainippon Pharma America, Inc.	Jul 2009	100%	March 31	166	Holding company, shared service for general management operations
Sunovion Pharmaceuticals Inc.	Jan 1984	100%	March 31	1,251*	Manufacturing and sales of pharmaceuticals
Sumitomo Dainippon Pharma Oncology, Inc.	Nov 2006	100%	March 31	193	R&D in the oncology area
Sumitovant Biopharma, Inc.	Oct 2019	100%	March 31	79	Implement oversight of Sumitovant group companies and formulation of potential business strategies for consideration of its group companies
Myovant Sciences Ltd.	Feb 2016	53%	March 31	538*	R&D, manufacturing and sales of pharmaceuticals in the women's health, prostate cancer area
Urovant Sciences Ltd.	Jan 2016	100%	March 31	290*	R&D, manufacturing and sales of pharmaceuticals in the urology area
Enzyvant Therapeutics Ltd.	Jan 2016	100%	March 31	26*	R&D in the pediatric rare diseases area
Altavant Sciences Ltd.	Sep 2017	100%	March 31	21*	R&D in the respiratory rare diseases area
Spirovant Sciences Ltd.	Feb 2019	100%	March 31	25*	R&D in the cystic fibrosis gene therapy area
Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.	Dec 2003	100%	March 31	764	Manufacturing and sales of pharmaceuticals


* Include employees of consolidated subsidiaries

Shareholder Data

Principal shareholders (As of March 31, 2021)

Name of Shareholders	No. of Shares Held (Thousands of Shares)	Percentage of Shareholding
Sumitomo Chemical Co., Ltd.	205,634	51.76
The Master Trust Bank of Japan, Ltd. (Trust account)	31,715	7.98
Inabata & Co., Ltd.	16,782	4.22
Custody Bank of Japan, Ltd. (Trust account)	12,828	3.23
Nippon Life Insurance Company	7,581	1.91
SMBC Trust Bank Ltd. (Trust account for Sumitomo Mitsui Banking Corporation's retirement benefits)	7,000	1.76
Sumitomo Life Insurance Company	5,776	1.45
Custody Bank of Japan, Ltd. (Trust account 7)	4,145	1.04
Sumitomo Dainippon Pharma Employee shareholders' association	2,934	0.74
Aioi Nissay Dowa Insurance Co., Ltd.	2,661	0.67

Composition of shareholders (As of March 31, 2021)



Share price range and trading volume

Share Price

(Yen)

Trading Volume

(Thousands of shares)

